The UK's Mereo BioPharma Group Ltd. has bagged another big pharma shareholder as part of a licensing deal to develop an AstraZeneca PLC compound, which is being developed for the genetic orphan disease alpha-1 antitrypsin deficiency (AATD).
AZ Licensing Deal Boosts Mereo Orphan Disease Model
UK group Mereo BioPharma is paying a very reasonable $5m to get its hands on AstraZeneca’s Phase II compound for the rare genetic disorder AATD.
